Hey Leute was meint ihr, zu Amazon Biotech ?
In den letzen Tagen hat sich was getan. Ob es wohl weiter nach steil bergauf geht ?
Mfg aus dem Schwabenland
Top-News
Amazon Biotech, Kursrakete ???
Beiträge:
8
Zugriffe: 1.059 / Heute: 1
Zugriffe: 1.059 / Heute: 1
|
Hey Leute was meint ihr, zu Amazon Biotech ?
In den letzen Tagen hat sich was getan. Ob es wohl weiter nach steil bergauf geht ?
Mfg aus dem Schwabenland
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR MSCI Europe Financials UCITS ETF
Perf. 12M: +44,40%
SPDR MSCI World Financials UCITS ETF
Perf. 12M: +37,11%
SPDR S&P U.S. Utilities Select Sector UCITS ETF
Perf. 12M: +35,85%
SPDR S&P U.S. Financials Select Sector UCITS ETF
Perf. 12M: +35,76%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +35,31%
Gibt viele News zu dem Wert, aber ohne Chart, ohne Kürzel, habe ich keine Meinung.
AMAZON BIOTECH INC - Nasdaq OTC BB: AMZB (NEW charting help)
<!--VITALS="app:interactivecharting lic:destination sale:kek web:kjb ops:ccn tech:cdt"-->Enter Symbol or Keyword:Time Frame: 1-day2 days5 days10 days----------1 month2 months3 months6 monthsYTD1 year2 years3 years4 years5 years1 decadeAll Data Additional chart controls
AMZB - Amazon Biotech Inc (OTC BB)3/31/2006
Trotz der News, würde ich Abstand nehmen. Ein OTC WERT ! oder mit nur sehr wenig Geld reingehen.
Schau mal Innospec an., ein WErt mit dem du 100 % machenkansnt in einem jahr. Aber sicherer als in dem WErt..
Schau dir mal NABI an
NABI BIOPHARMACEUTICALS - Nasdaq National Market: NABI (NEW charting help)
<!--VITALS="app:interactivecharting lic:destination sale:kek web:kjb ops:ccn tech:cdt"-->
| |||||||||||||||
http://www.ariva.de/board/245179/...chlist/watchlist.m&a=&702
Sehe dir diese Werte an!!
ElN usw.
Amazon Biotech Announces Preparation of a Protocol to Test AMZ0026 as an HIV Drug to Delay Onset of Full-Blown AIDS
Tuesday March 28, 5:53 pm ET
NEW YORK, March 28, 2006 (PRIMEZONE) -- Amazon Biotech, Inc. today announced that it is designing a protocol to test AMZ0026 as an HIV drug to delay onset of full-blown AIDS. The study is designed to include 60 non-symptomatic HIV-infected subjects who have not been recently treated with any AIDS medications. AMZ0026 versus placebo will be administered for a 6 month treatment period, during which primary endpoint parameters will be monitored, including ``T'' Cell increases and the amount of HIV virus in the bloodstream.
The drug formulation is based upon the Amazon Biotech, Inc. philosophy of several active ingredients working in combination, utilizing cutting edge whole plant pharmaceutical drug technology to create a natural, healthier pharmaceutical drug.
The current guidelines of the DHHS recommend deferring initiation of conventional anti-retroviral therapy at least until the patient's CD4 (helper T cell) count reaches 350 cells/mm3 or less, in order to ``avoid treatment-related negative effects on quality of life and drug-related toxicities, to preserve future treatment options and to delay the development of drug resistance if there is incomplete viral suppression.''
A number of AIDS vaccines are in developmental stages, but none have been approved to date, with the stark fact remaining that approximately 40,000 people are infected with HIV each year in the United States alone. The need to prevent transition of HIV to Clinical AIDS is equally apparent when considering that over 3,000,000 people died of AIDS in 2005 (www.cdc.gov/hiv/PUBS/Facts/At-A-Glance.htm and UNAIDS).
Amazon Biotech strives to fill the obvious need for an AIDS prophylactic agent to treat HIV-infected individuals before they develop clinical (symptomatic) AIDS. The new AMZ0026 HIV protocol is designed to evaluate this breakthrough investigational drug's ability to prevent the progression to AIDS in HIV-infected individuals through assessment of AMZ0026's effect on benchmark clinical markers for AIDS in this six month study.
The protocol is expected to be submitted shortly to the FDA as part of an existing IND (Investigational New Drug Application). More details will follow.
A parallel study in the symptomatic AIDS population is also in preparation and will be announced in a separate press release.
Tuesday March 28, 5:53 pm ET
NEW YORK, March 28, 2006 (PRIMEZONE) -- Amazon Biotech, Inc. today announced that it is designing a protocol to test AMZ0026 as an HIV drug to delay onset of full-blown AIDS. The study is designed to include 60 non-symptomatic HIV-infected subjects who have not been recently treated with any AIDS medications. AMZ0026 versus placebo will be administered for a 6 month treatment period, during which primary endpoint parameters will be monitored, including ``T'' Cell increases and the amount of HIV virus in the bloodstream.
The drug formulation is based upon the Amazon Biotech, Inc. philosophy of several active ingredients working in combination, utilizing cutting edge whole plant pharmaceutical drug technology to create a natural, healthier pharmaceutical drug.
The current guidelines of the DHHS recommend deferring initiation of conventional anti-retroviral therapy at least until the patient's CD4 (helper T cell) count reaches 350 cells/mm3 or less, in order to ``avoid treatment-related negative effects on quality of life and drug-related toxicities, to preserve future treatment options and to delay the development of drug resistance if there is incomplete viral suppression.''
A number of AIDS vaccines are in developmental stages, but none have been approved to date, with the stark fact remaining that approximately 40,000 people are infected with HIV each year in the United States alone. The need to prevent transition of HIV to Clinical AIDS is equally apparent when considering that over 3,000,000 people died of AIDS in 2005 (www.cdc.gov/hiv/PUBS/Facts/At-A-Glance.htm and UNAIDS).
Amazon Biotech strives to fill the obvious need for an AIDS prophylactic agent to treat HIV-infected individuals before they develop clinical (symptomatic) AIDS. The new AMZ0026 HIV protocol is designed to evaluate this breakthrough investigational drug's ability to prevent the progression to AIDS in HIV-infected individuals through assessment of AMZ0026's effect on benchmark clinical markers for AIDS in this six month study.
The protocol is expected to be submitted shortly to the FDA as part of an existing IND (Investigational New Drug Application). More details will follow.
A parallel study in the symptomatic AIDS population is also in preparation and will be announced in a separate press release.
Es gibt keine neuen Beiträge.
Neueste Beiträge aus dem HOMELAND SEC. CAP. DL-001 Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
3 | 304 | $$ Subpenny mit Revenueexplosion$$ | Calibra21 | Fintelwuselwix | 21.11.07 18:52 | |
| 7 | **Trading-Chance zum Wochenauftakt** | Nukem | Nukem | 15.08.06 09:41 | ||
| 7 | Amazon Biotech, Kursrakete ??? | Bobby333 | Bobby333 | 02.04.06 07:55 | ||
| 1 | HOMELAND Sec. vom Handel ausgesetzt ? | zondas | dackeli | 28.02.06 19:01 |
